- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Remote Scanning Support Platform for MRI, CT and PET/CT
The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
The Food and Drug Administration (FDA) has granted 510(k) clearance for nCommand Lite, a multimodality platform that allows remote viewing of advanced imaging scans as well as access to real-time expert guidance for on-site technologists.
Developed by IONIC Health, nCommand Lite features real-time remote support on a vendor-agnostic platform for a variety of modalities including computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT).
The nCommand Lite, which will be distributed by GE HealthCare, may also be utilized for remote training as well as evaluation of scanning parameters and procedure assessments. GE HealthCare added that the nCommand Lite platform may provide enhance access to advanced imaging for patients and provide flexibility to facilities grappling with radiology workforce shortages.
“Our goal is to provide remote operations solutions that lead to increased access for patients, including patients who may require complex care and support from an off-site expert technologist,” said Rekha Ranganathan, senior vice president and general manager of Imaging Platforms and Digital Solutions, GE HealthCare. “Additionally, we recognize that health-care systems are not only looking to leverage the skills of one expert across multiple physical locations for knowledge sharing and training but have an imaging fleet that includes multiple vendors and modalities, so it was critical for us to expand our remote operations portfolio by adding IONIC Health’s nCommand Lite technology.”
(Editor's note: To subscribe to our e-newsletter, click here.)
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
